Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered
in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.